in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Wockhardt Poised for U.S. Drug Launch
1:20 PM MDT | July 31, 2007 | DR
Wockhardt (Mumbai), a pharmaceuticals and biotechnology company, has received tentative approval from the U.S. FDA to market terbinafine tablets in the U.S. Terbinafine is the generic version of Novartis’s branded drug Lamisil. The U.S. product patent for Lamisil expires on June 29. The U.S. market for terbinafine tablets, which are used to treat fungal infections, is estimated to be worth $680 million/year. “Our Wockhardt USA team is ready to embark on the launch of terbinafine the day the product patent expires,” says Habil Khorakiwala...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee